Free Trial
Your $100 Credit Expires Tomorrow! Get MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion

Amgen (AMGN) Financials

Amgen logo
$339.30 +1.88 (+0.56%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$340.28 +0.98 (+0.29%)
As of 05/22/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Amgen

Annual Income Statements for Amgen

This table shows Amgen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
6,939 7,722 1,979 8,394 7,842 7,264 5,893 6,552 6,717 4,090 7,711
Consolidated Net Income / (Loss)
6,939 7,722 1,979 8,394 7,842 7,264 5,893 6,552 6,717 4,090 7,711
Net Income / (Loss) Continuing Operations
6,939 7,722 1,979 8,394 7,842 7,264 5,893 6,552 6,717 4,090 7,711
Total Pre-Tax Income
7,978 9,163 9,597 9,545 9,138 8,133 6,701 7,346 7,855 4,609 8,976
Total Operating Income
8,470 9,794 9,973 10,263 9,674 9,139 7,639 9,566 7,897 7,258 9,080
Total Gross Profit
17,435 18,829 18,780 19,646 19,006 19,265 19,525 19,917 19,739 20,566 24,714
Total Revenue
21,662 22,991 22,849 23,747 23,362 25,424 25,979 26,323 28,190 33,424 36,751
Total Cost of Revenue
4,227 4,162 4,069 4,101 4,356 6,159 6,454 6,406 8,451 12,858 12,037
Operating Cost of Revenue
4,227 4,162 4,069 4,101 4,356 6,159 6,454 6,406 8,451 12,858 12,037
Total Operating Expenses
8,965 9,035 8,807 9,383 9,332 10,126 11,886 10,351 11,842 13,308 15,634
Selling, General & Admin Expense
4,895 5,195 5,245 5,646 5,216 5,919 5,562 5,917 7,058 7,344 8,362
Research & Development Expense
4,070 3,840 3,562 3,737 4,116 4,207 6,324 4,434 4,784 5,964 7,272
Total Other Income / (Expense), net
-492 -631 -376 -718 -536 -1,006 -938 -2,220 -42 -2,649 -104
Interest Expense
1,095 1,260 1,304 1,392 1,289 1,262 1,197 1,406 2,875 3,155 2,755
Other Income / (Expense), net
603 629 928 674 753 256 259 -814 2,833 506 2,651
Income Tax Expense
1,039 1,441 7,618 1,151 1,296 869 808 794 1,138 519 1,265
Basic Earnings per Share
$9.15 $10.32 $2.71 $12.70 $12.96 $12.40 $10.34 $12.18 $12.56 $7.62 $14.33
Weighted Average Basic Shares Outstanding
758M 748M 731M 661M 605M 586M 570M 538M 535M 537M 538M
Diluted Earnings per Share
$9.06 $10.24 $2.69 $12.62 $12.88 $12.31 $10.28 $12.11 $12.49 $7.56 $14.23
Weighted Average Diluted Shares Outstanding
766M 754M 735M 665M 609M 590M 573M 541M 538M 541M 542M
Weighted Average Basic & Diluted Shares Outstanding
758.40M 748.30M 730.30M 660.90M 589.81M 577.57M 557.03M 533.98M 535.92M 537.20M 539.07M

Quarterly Income Statements for Amgen

This table shows Amgen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
1,730 767 -113 746 2,830 627 1,730 1,432 3,216 1,333 1,819
Consolidated Net Income / (Loss)
1,730 767 -113 746 2,830 627 1,730 1,432 3,216 1,333 1,819
Net Income / (Loss) Continuing Operations
1,730 767 -113 746 2,830 627 1,730 1,432 3,216 1,333 1,819
Total Pre-Tax Income
1,947 852 -68 794 3,101 782 1,973 1,568 3,921 1,514 2,084
Total Operating Income
2,021 1,271 991 1,909 2,047 2,311 1,178 2,656 2,526 2,720 2,666
Total Gross Profit
5,097 5,084 4,247 5,152 5,193 5,974 5,181 6,168 6,475 6,890 5,874
Total Revenue
6,903 8,196 7,447 8,388 8,503 9,086 8,149 9,179 9,557 9,866 8,618
Total Cost of Revenue
1,806 3,112 3,200 3,236 3,310 3,112 2,968 3,011 3,082 2,976 2,744
Operating Cost of Revenue
1,806 3,112 3,200 3,236 3,310 3,112 2,968 3,011 3,082 2,976 2,744
Total Operating Expenses
3,076 3,813 3,256 3,243 3,146 3,663 4,003 3,512 3,949 4,170 3,208
Selling, General & Admin Expense
1,353 3,153 1,913 1,796 1,696 2,126 1,687 1,768 2,049 2,028 1,602
Research & Development Expense
1,079 1,534 1,343 1,447 1,450 1,724 1,486 1,744 1,900 2,142 1,719
Other Special Charges / (Income)
- - - - - - 830 - - - -113
Total Other Income / (Expense), net
-74 -419 -1,059 -1,115 1,054 -1,529 795 -1,088 1,395 -1,206 -582
Interest Expense
759 821 824 808 776 747 723 694 685 653 657
Other Income / (Expense), net
685 402 -235 -307 1,830 -782 1,518 -394 2,080 -553 75
Income Tax Expense
217 85 45 48 271 155 243 136 705 181 265
Basic Earnings per Share
$3.23 $1.43 ($0.21) $1.39 $5.27 $1.17 $3.22 $2.66 $5.98 $2.47 $3.37
Weighted Average Basic Shares Outstanding
535M 535M 536M 537M 537M 537M 538M 538M 538M 538M 540M
Diluted Earnings per Share
$3.22 $1.42 ($0.21) $1.38 $5.22 $1.17 $3.20 $2.65 $5.93 $2.45 $3.34
Weighted Average Diluted Shares Outstanding
538M 538M 536M 541M 542M 541M 541M 541M 542M 542M 544M
Weighted Average Basic & Diluted Shares Outstanding
535.18M 535.92M 536.43M 537.33M 537.53M 537.20M 537.71M 538.36M 538.48M 539.07M 539.71M
Cash Dividends to Common per Share
$2.13 - $2.25 - - - $2.38 - - - $2.52

Annual Cash Flow Statements for Amgen

This table details how cash moves in and out of Amgen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
413 -903 559 3,145 -908 229 1,723 -360 3,315 1,029 -2,844
Net Cash From Operating Activities
9,731 10,354 11,177 11,296 9,150 10,497 9,261 9,721 8,471 11,490 9,958
Net Cash From Continuing Operating Activities
9,731 10,354 10,509 11,296 8,842 10,497 9,261 9,721 8,471 11,490 9,958
Net Income / (Loss) Continuing Operations
6,939 7,722 1,979 8,394 7,842 7,264 5,893 6,552 6,717 4,090 7,711
Consolidated Net Income / (Loss)
6,939 7,722 1,979 8,394 7,842 7,264 5,893 6,552 6,717 4,090 7,711
Depreciation Expense
2,108 2,105 1,955 1,946 2,206 3,601 3,398 3,417 4,071 5,592 5,167
Non-Cash Adjustments To Reconcile Net Income
176 343 663 697 -186 135 1,617 1,683 -560 671 -221
Changes in Operating Assets and Liabilities, net
508 184 6,580 259 -1,020 -503 -1,647 -1,931 -1,757 1,137 -2,699
Net Cash From Investing Activities
-5,547 -8,658 -4,024 14,339 5,709 -5,401 733 -6,044 -26,204 -1,046 -1,943
Net Cash From Continuing Investing Activities
-5,547 -8,658 -4,024 14,339 5,709 -5,401 733 -6,044 -26,204 -1,046 -1,943
Purchase of Property, Plant & Equipment
-594 -738 -664 -738 -618 -608 -880 -936 -1,112 -1,096 -1,858
Acquisitions
-359 0.00 -19 -40 -13,641 -3,219 -2,529 -3,839 -26,989 0.00 -53
Sale and/or Maturity of Investments
21,556 20,417 30,414 33,768 29,390 6,978 13,234 1,218 1,673 0.00 0.00
Other Investing Activities, net
-447 -243 -148 -105 -28 -75 -192 100 224 50 -32
Net Cash From Financing Activities
-3,771 -2,599 -6,594 -22,490 -15,767 -4,867 -8,271 -4,037 21,048 -9,415 -10,859
Net Cash From Continuing Financing Activities
-3,771 -2,599 -6,594 -22,490 -15,767 -4,867 -8,271 -4,037 21,048 -9,415 -10,859
Repayment of Debt
-2,319 - -4,405 -1,189 -4,556 -6,540 -4,228 -400 -2,173 -4,383 -5,735
Repurchase of Common Equity
-1,867 - -3,160 -17,794 -7,702 -3,486 -4,975 -6,360 0.00 -200 0.00
Payment of Dividends
-2,396 - -3,365 -3,507 -3,509 -3,755 -4,013 -4,196 -4,556 -4,832 -5,124
Issuance of Debt
3,465 - 4,527 0.00 0.00 8,914 4,945 6,919 27,777 0.00 0.00

Quarterly Cash Flow Statements for Amgen

This table details how cash moves in and out of Amgen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
493 -23,797 -1,236 -407 -290 2,962 -3,163 -782 1,417 -316 2,909
Net Cash From Operating Activities
2,760 538 689 2,459 3,571 4,771 1,391 2,280 4,684 1,603 2,189
Net Cash From Continuing Operating Activities
2,760 538 689 2,459 3,571 4,771 1,391 2,280 4,684 1,603 2,189
Net Income / (Loss) Continuing Operations
1,730 767 -113 746 2,830 627 1,730 1,432 3,216 1,333 1,819
Consolidated Net Income / (Loss)
1,730 767 -113 746 2,830 627 1,730 1,432 3,216 1,333 1,819
Depreciation Expense
895 1,380 1,399 1,400 1,396 1,397 1,387 1,341 1,307 1,132 1,116
Non-Cash Adjustments To Reconcile Net Income
529 -88 496 574 -1,401 1,002 -460 688 -1,472 1,023 151
Changes in Operating Assets and Liabilities, net
-394 -1,521 -1,093 -261 746 1,745 -1,266 -1,181 1,633 -1,885 -897
Net Cash From Investing Activities
-262 -27,089 -217 -217 -210 -402 -447 -389 -414 -693 -716
Net Cash From Continuing Investing Activities
-262 -27,089 -217 -217 -210 -402 -447 -389 -414 -693 -716
Purchase of Property, Plant & Equipment
-248 -249 -230 -238 -257 -371 -411 -369 -436 -642 -712
Other Investing Activities, net
-14 152 13 21 47 -31 -36 -20 22 2.00 -4.00
Net Cash From Financing Activities
-2,005 2,754 -1,708 -2,649 -3,651 -1,407 -4,107 -2,673 -2,853 -1,226 1,436
Net Cash From Continuing Financing Activities
-2,005 2,754 -1,708 -2,649 -3,651 -1,407 -4,107 -2,673 -2,853 -1,226 1,436
Repayment of Debt
-866 -102 -500 -1,440 -2,441 -2.00 -2,828 -1,393 -1,571 57 -1,170
Payment of Dividends
-1,140 -1,140 -1,208 -1,209 -1,210 -1,205 -1,279 -1,280 -1,282 -1,283 -1,358
Issuance of Debt
1.00 3,996 - - - - 0.00 - - - 3,964

Annual Balance Sheets for Amgen

This table presents Amgen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
71,449 77,626 79,954 66,416 59,707 62,948 61,165 65,121 97,154 91,839 90,586
Total Current Assets
38,515 46,010 49,476 37,618 18,440 21,144 19,385 22,186 30,332 29,030 29,057
Cash & Equivalents
4,144 3,241 3,800 6,945 6,037 6,266 7,989 7,629 10,944 11,973 9,129
Accounts Receivable
2,995 3,165 3,237 3,580 4,057 4,525 4,895 5,563 7,268 6,782 9,570
Inventories, net
2,435 2,745 2,834 2,940 3,584 3,893 4,086 4,930 9,518 6,998 6,225
Other Current Assets
1,703 2,015 1,727 1,794 1,888 2,079 2,367 2,388 2,602 3,277 4,133
Plant, Property, & Equipment, net
4,907 4,961 4,989 4,958 4,928 4,889 5,184 5,427 5,941 6,543 7,913
Total Noncurrent Assets
28,027 26,655 25,489 23,840 36,339 36,915 36,596 37,508 60,881 56,266 53,616
Goodwill
14,787 14,751 14,761 14,699 14,703 14,689 14,890 15,529 18,629 18,637 18,680
Intangible Assets
11,641 10,279 8,609 7,443 19,413 16,587 15,182 16,080 32,641 27,699 22,276
Other Noncurrent Operating Assets
1,599 1,625 2,119 1,698 2,223 5,639 6,524 5,899 9,611 9,930 12,660
Total Liabilities & Shareholders' Equity
71,449 77,626 79,954 66,416 59,707 62,948 61,165 65,121 97,154 91,839 90,586
Total Liabilities
43,366 47,751 54,713 53,916 50,034 53,539 54,465 61,460 90,922 85,962 81,928
Total Current Liabilities
8,664 11,204 9,020 13,488 12,835 11,653 12,184 15,687 18,392 23,099 25,489
Short-Term Debt
2,247 4,403 1,152 4,419 2,953 91 87 1,591 1,443 3,550 4,599
Accounts Payable
965 917 1,352 1,207 1,371 1,421 1,366 1,572 1,590 1,908 2,367
Accrued Expenses
5,452 5,884 6,516 7,862 8,511 10,141 10,731 12,524 15,359 17,641 18,523
Total Noncurrent Liabilities
34,702 36,547 45,693 40,428 37,199 41,886 42,281 45,773 72,530 62,863 56,439
Long-Term Debt
29,182 30,193 34,190 29,510 26,950 32,895 33,222 37,354 63,170 56,549 50,005
Noncurrent Deferred & Payable Income Tax Liabilities
4,212 4,855 10,265 9,634 8,037 6,968 6,594 5,768 7,034 3,965 4,056
Other Noncurrent Operating Liabilities
1,308 1,499 1,238 1,284 2,212 2,023 2,465 2,651 2,326 2,349 2,378
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
28,083 29,875 25,241 12,500 9,673 9,409 6,700 3,661 6,232 5,877 8,658
Total Preferred & Common Equity
28,083 29,875 25,241 12,500 9,673 9,409 6,700 3,661 6,232 5,877 8,658
Total Common Equity
28,083 29,875 25,241 12,500 9,673 9,409 6,700 3,661 6,232 5,877 8,658
Common Stock
30,649 30,784 30,992 31,246 31,531 31,802 32,096 32,514 33,070 33,533 34,023
Retained Earnings
-2,086 -438 -5,072 -17,977 -21,330 -21,408 -24,600 -28,622 -26,549 -27,590 -25,107
Accumulated Other Comprehensive Income / (Loss)
-480 -471 -679 -769 -528 -985 -796 -231 -289 -66 -258

Quarterly Balance Sheets for Amgen

This table presents Amgen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
90,269 90,534 97,154 92,980 90,907 90,883 91,839 89,367 87,897 90,141 92,504
Total Current Assets
47,380 48,477 30,332 28,029 27,206 26,766 29,030 26,929 26,734 27,885 31,475
Cash & Equivalents
34,248 34,741 10,944 9,708 9,301 9,011 11,973 8,810 8,028 9,445 12,038
Accounts Receivable
5,830 6,145 7,268 6,776 6,934 7,317 6,782 8,132 8,701 8,490 9,138
Inventories, net
4,978 5,026 9,518 8,724 7,995 7,362 6,998 6,729 6,583 6,346 6,186
Other Current Assets
2,324 2,565 2,602 2,821 2,976 3,076 3,277 3,258 3,422 3,604 4,113
Plant, Property, & Equipment, net
5,532 5,563 5,941 6,002 6,097 6,156 6,543 6,681 6,855 7,220 8,216
Total Noncurrent Assets
37,357 36,494 60,881 58,949 57,604 57,961 56,266 55,757 54,308 55,036 52,813
Goodwill
15,531 15,509 18,629 18,570 18,616 18,658 18,637 18,645 18,674 18,676 18,674
Intangible Assets
14,633 13,150 32,641 31,372 30,172 28,920 27,699 25,724 24,614 23,139 21,379
Other Noncurrent Operating Assets
7,193 7,835 9,611 9,007 8,816 10,383 9,930 11,388 11,020 13,221 12,760
Total Liabilities & Shareholders' Equity
90,269 90,534 97,154 92,980 90,907 90,883 91,839 89,367 87,897 90,141 92,504
Total Liabilities
83,488 82,878 90,922 87,958 84,982 83,356 85,962 83,160 80,469 80,522 83,314
Total Current Liabilities
17,097 16,954 18,392 19,714 21,517 20,312 23,099 23,008 20,476 21,791 24,955
Short-Term Debt
2,167 1,428 1,443 3,959 5,528 3,544 3,550 3,368 2,444 2,153 5,437
Accounts Payable
1,212 1,358 1,590 1,628 2,267 2,147 1,908 2,406 3,010 2,838 2,935
Accrued Expenses
13,718 14,168 15,359 14,127 13,722 14,621 17,641 17,234 15,022 16,800 16,583
Total Noncurrent Liabilities
66,391 65,924 72,530 68,244 63,465 63,044 62,863 60,152 59,993 58,731 58,359
Long-Term Debt
59,377 59,040 63,170 60,061 57,117 56,854 56,549 54,013 53,760 52,434 51,886
Noncurrent Deferred & Payable Income Tax Liabilities
4,478 4,579 7,034 5,826 3,985 3,991 3,965 3,929 3,897 4,074 4,108
Other Noncurrent Operating Liabilities
2,536 2,305 2,326 2,357 2,363 2,199 2,349 2,210 2,336 2,223 2,365
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
6,781 7,656 6,232 5,022 5,925 7,527 5,877 6,207 7,428 9,619 9,190
Total Preferred & Common Equity
6,781 7,656 6,232 5,022 5,925 7,527 5,877 6,207 7,428 9,619 9,190
Total Common Equity
6,781 7,656 6,232 5,022 5,925 7,527 5,877 6,207 7,428 9,619 9,190
Common Stock
32,601 32,753 33,070 33,082 33,204 33,393 33,533 33,578 33,680 33,841 34,030
Retained Earnings
-25,540 -24,971 -26,549 -27,870 -27,124 -25,530 -27,590 -27,140 -25,708 -23,800 -24,650
Accumulated Other Comprehensive Income / (Loss)
-280 -126 -289 -190 -155 -336 -66 -231 -544 -422 -190

Annual Metrics And Ratios for Amgen

This table displays calculated financial ratios and metrics derived from Amgen's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
7.97% 6.14% -0.62% 3.93% -1.62% 8.83% 2.18% 1.32% 7.09% 18.57% 9.95%
EBITDA Growth
27.81% 12.05% 2.62% 0.21% -1.94% 2.87% -13.08% 7.73% 21.63% -9.76% 26.52%
EBIT Growth
36.31% 14.88% 4.59% 0.33% -4.66% -9.90% -15.93% 10.81% 22.60% -27.64% 51.09%
NOPAT Growth
28.84% 12.04% -75.08% 338.87% -8.02% -1.68% -17.70% 27.00% -20.85% -4.62% 21.11%
Net Income Growth
34.53% 11.28% -74.37% 324.15% -6.58% -7.37% -18.87% 11.18% 2.52% -39.11% 88.53%
EPS Growth
35.22% 13.02% -73.73% 369.15% 2.06% -4.43% -16.49% 17.80% 3.14% -39.47% 88.23%
Operating Cash Flow Growth
8.70% 6.40% 7.95% 1.06% -19.00% 14.72% -11.77% 4.97% -12.86% 35.64% -13.33%
Free Cash Flow Firm Growth
13.60% 14.87% -4.60% 13.29% -148.48% 235.16% -8.27% 10.92% -375.54% 162.17% -37.84%
Invested Capital Growth
-4.54% -6.20% -28.35% -9.42% 79.07% 3.53% 0.71% 4.16% 79.88% -9.85% 0.24%
Revenue Q/Q Growth
0.96% 1.90% -0.71% 1.84% -0.14% 1.75% 0.82% -0.03% 5.06% 2.74% 2.17%
EBITDA Q/Q Growth
6.34% 3.56% -1.34% 0.25% -0.32% 0.64% 2.26% -1.97% -0.14% -0.94% 2.26%
EBIT Q/Q Growth
7.72% 4.14% -0.59% -0.08% -2.37% -0.94% 3.55% -3.35% -4.37% -1.82% 5.75%
NOPAT Q/Q Growth
6.61% 2.40% -76.20% 287.53% -3.96% -0.35% 5.16% 0.08% -11.80% 14.58% 5.87%
Net Income Q/Q Growth
7.87% 1.78% -75.80% 281.20% -2.79% -1.20% 5.06% -4.14% -11.22% -3.31% 10.08%
EPS Q/Q Growth
8.11% 2.30% -75.66% 230.37% -1.30% -0.81% 5.87% -2.65% -11.23% -3.20% 9.88%
Operating Cash Flow Q/Q Growth
-7.32% 11.01% -0.78% 1.64% -6.92% -3.32% 7.61% -1.61% -19.95% 58.33% -24.14%
Free Cash Flow Firm Q/Q Growth
2.02% 16.90% -5.60% 6.69% -168.61% 246.57% 1.47% -31.54% -485.17% 161.97% -33.42%
Invested Capital Q/Q Growth
-1.67% -6.15% -29.07% -9.18% 54.37% -3.46% -2.75% 7.84% 79.44% -8.34% -1.15%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
80.49% 81.90% 82.19% 82.73% 81.35% 75.77% 75.16% 75.66% 70.02% 61.53% 67.25%
EBITDA Margin
51.62% 54.49% 56.27% 54.25% 54.08% 51.12% 43.48% 46.23% 52.50% 39.96% 45.98%
Operating Margin
39.10% 42.60% 43.65% 43.22% 41.41% 35.95% 29.40% 36.34% 28.01% 21.71% 24.71%
EBIT Margin
41.88% 45.34% 47.71% 46.06% 44.63% 36.95% 30.40% 33.25% 38.06% 23.23% 31.92%
Profit (Net Income) Margin
32.03% 33.59% 8.66% 35.35% 33.57% 28.57% 22.68% 24.89% 23.83% 12.24% 20.98%
Tax Burden Percent
86.98% 84.27% 20.62% 87.94% 85.82% 89.32% 87.94% 89.19% 85.51% 88.74% 85.91%
Interest Burden Percent
87.93% 87.91% 88.04% 87.27% 87.64% 86.57% 84.84% 83.94% 73.21% 59.36% 76.52%
Effective Tax Rate
13.02% 15.73% 79.38% 12.06% 14.18% 10.68% 12.06% 10.81% 14.49% 11.26% 14.09%
Return on Invested Capital (ROIC)
25.58% 30.28% 9.08% 50.10% 34.74% 26.16% 21.09% 26.14% 14.49% 11.31% 14.43%
ROIC Less NNEP Spread (ROIC-NNEP)
2.67% 61.18% 10.66% 123.91% 31.15% 22.01% 17.62% 18.93% 14.40% 6.69% 14.24%
Return on Net Nonoperating Assets (RNNOA)
0.19% -3.63% -1.90% -5.62% 35.99% 49.98% 52.08% 100.33% 121.30% 56.24% 91.68%
Return on Equity (ROE)
25.77% 26.65% 7.18% 44.48% 70.73% 76.13% 73.16% 126.47% 135.79% 67.55% 106.10%
Cash Return on Invested Capital (CROIC)
30.22% 36.68% 42.12% 59.98% -21.92% 22.69% 20.38% 22.07% -42.59% 21.67% 14.19%
Operating Return on Assets (OROA)
12.92% 13.98% 13.84% 14.94% 16.53% 15.32% 12.73% 13.86% 13.22% 8.22% 12.86%
Return on Assets (ROA)
9.88% 10.36% 2.51% 11.47% 12.44% 11.84% 9.50% 10.38% 8.28% 4.33% 8.45%
Return on Common Equity (ROCE)
25.77% 26.65% 7.18% 44.48% 70.73% 76.13% 73.16% 126.47% 135.79% 67.55% 106.10%
Return on Equity Simple (ROE_SIMPLE)
24.71% 25.85% 7.84% 67.15% 81.07% 77.20% 87.96% 178.97% 107.78% 69.59% 0.00%
Net Operating Profit after Tax (NOPAT)
7,367 8,254 2,057 9,025 8,302 8,163 6,718 8,532 6,753 6,441 7,800
NOPAT Margin
34.01% 35.90% 9.00% 38.01% 35.54% 32.11% 25.86% 32.41% 23.96% 19.27% 21.22%
Net Nonoperating Expense Percent (NNEP)
22.91% -30.90% -1.58% -73.81% 3.59% 4.15% 3.47% 7.21% 0.09% 4.62% 0.19%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 20.03% 9.53% 9.76% 12.33%
Cost of Revenue to Revenue
19.51% 18.10% 17.81% 17.27% 18.65% 24.23% 24.84% 24.34% 29.98% 38.47% 32.75%
SG&A Expenses to Revenue
22.60% 22.60% 22.96% 23.78% 22.33% 23.28% 21.41% 22.48% 25.04% 21.97% 22.75%
R&D to Revenue
18.79% 16.70% 15.59% 15.74% 17.62% 16.55% 24.34% 16.84% 16.97% 17.84% 19.79%
Operating Expenses to Revenue
41.39% 39.30% 38.54% 39.51% 39.95% 39.83% 45.75% 39.32% 42.01% 39.82% 42.54%
Earnings before Interest and Taxes (EBIT)
9,073 10,423 10,901 10,937 10,427 9,395 7,898 8,752 10,730 7,764 11,731
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
11,181 12,528 12,856 12,883 12,633 12,996 11,296 12,169 14,801 13,356 16,898
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.35 2.87 4.05 8.27 12.72 12.55 17.34 35.62 23.82 23.65 20.22
Price to Tangible Book Value (P/TBV)
56.78 17.68 54.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
4.34 3.73 4.47 4.35 5.27 4.65 4.47 4.95 5.27 4.16 4.76
Price to Earnings (P/E)
13.54 11.09 51.65 12.32 15.69 16.26 19.71 19.91 22.10 33.98 22.70
Dividend Yield
2.54% 3.47% 3.27% 3.25% 2.80% 3.15% 4.27% 3.17% 3.07% 3.48% 2.93%
Earnings Yield
7.38% 9.01% 1.94% 8.12% 6.37% 6.15% 5.07% 5.02% 4.53% 2.94% 4.41%
Enterprise Value to Invested Capital (EV/IC)
3.34 3.11 5.07 6.31 4.70 4.42 4.42 4.81 3.37 3.46 4.07
Enterprise Value to Revenue (EV/Rev)
4.34 3.57 4.20 4.55 6.16 5.53 5.44 6.08 7.17 5.60 6.00
Enterprise Value to EBITDA (EV/EBITDA)
8.41 6.56 7.46 8.38 11.40 10.81 12.52 13.15 13.65 14.01 13.05
Enterprise Value to EBIT (EV/EBIT)
10.36 7.88 8.79 9.88 13.81 14.95 17.91 18.29 18.83 24.10 18.80
Enterprise Value to NOPAT (EV/NOPAT)
12.76 9.96 46.62 11.97 17.35 17.21 21.05 18.76 29.93 29.05 28.27
Enterprise Value to Operating Cash Flow (EV/OCF)
9.66 7.94 8.58 9.56 15.74 13.38 15.27 16.47 23.86 16.28 22.14
Enterprise Value to Free Cash Flow (EV/FCFF)
10.80 8.22 10.05 10.00 0.00 19.84 21.78 22.22 0.00 15.16 28.75
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.12 1.16 1.40 2.71 3.09 3.51 4.97 10.64 10.37 10.23 6.31
Long-Term Debt to Equity
1.04 1.01 1.35 2.36 2.79 3.50 4.96 10.20 10.14 9.62 5.78
Financial Leverage
0.07 -0.06 -0.18 -0.05 1.16 2.27 2.96 5.30 8.42 8.41 6.44
Leverage Ratio
2.61 2.57 2.86 3.88 5.69 6.43 7.70 12.19 16.40 15.61 12.55
Compound Leverage Factor
2.29 2.26 2.52 3.38 4.99 5.56 6.54 10.23 12.01 9.27 9.60
Debt to Total Capital
52.81% 53.66% 58.34% 73.08% 75.56% 77.81% 83.25% 91.41% 91.20% 91.09% 86.31%
Short-Term Debt to Total Capital
3.78% 6.83% 1.90% 9.52% 7.46% 0.21% 0.22% 3.73% 2.04% 5.38% 7.27%
Long-Term Debt to Total Capital
49.04% 46.83% 56.44% 63.56% 68.10% 77.59% 83.04% 87.67% 89.17% 85.71% 79.04%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
47.19% 46.34% 41.66% 26.92% 24.44% 22.19% 16.75% 8.59% 8.80% 8.91% 13.69%
Debt to EBITDA
2.81 2.76 2.75 2.63 2.37 2.54 2.95 3.20 4.37 4.50 3.23
Net Debt to EBITDA
0.00 -0.28 -0.49 0.36 1.66 1.72 2.24 2.44 3.63 3.60 2.69
Long-Term Debt to EBITDA
2.61 2.41 2.66 2.29 2.13 2.53 2.94 3.07 4.27 4.23 2.96
Debt to NOPAT
4.27 4.19 17.19 3.76 3.60 4.04 4.96 4.56 9.57 9.33 7.00
Net Debt to NOPAT
0.01 -0.42 -3.08 0.51 2.53 2.74 3.76 3.47 7.95 7.47 5.83
Long-Term Debt to NOPAT
3.96 3.66 16.63 3.27 3.25 4.03 4.95 4.38 9.35 8.78 6.41
Altman Z-Score
2.48 2.35 2.37 2.11 2.06 1.93 1.71 1.63 1.40 1.27 1.77
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.45 4.11 5.49 2.79 1.44 1.81 1.59 1.41 1.65 1.26 1.14
Quick Ratio
3.97 3.68 4.98 2.44 1.01 1.30 1.06 0.95 0.99 0.81 0.73
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
8,704 9,998 9,538 10,805 -5,238 7,080 6,494 7,203 -19,847 12,339 7,670
Operating Cash Flow to CapEx
3,040.94% 1,402.98% 1,683.28% 1,530.62% 1,480.58% 1,726.48% 1,052.39% 1,038.57% 761.78% 1,048.36% 535.95%
Free Cash Flow to Firm to Interest Expense
7.95 7.93 7.31 7.76 -4.06 5.61 5.43 5.12 -6.90 3.91 2.78
Operating Cash Flow to Interest Expense
8.89 8.22 8.57 8.11 7.10 8.32 7.74 6.91 2.95 3.64 3.61
Operating Cash Flow Less CapEx to Interest Expense
8.59 7.63 8.06 7.58 6.62 7.84 7.00 6.25 2.56 3.29 2.94
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.31 0.31 0.29 0.32 0.37 0.41 0.42 0.42 0.35 0.35 0.40
Accounts Receivable Turnover
7.82 7.46 7.14 6.97 6.12 5.93 5.52 5.03 4.39 4.76 4.50
Inventory Turnover
1.66 1.61 1.46 1.42 1.34 1.65 1.62 1.42 1.17 1.56 1.82
Fixed Asset Turnover
4.28 4.66 4.59 4.77 4.73 5.18 5.16 4.96 4.96 5.35 5.08
Accounts Payable Turnover
4.31 4.42 3.59 3.21 3.38 4.41 4.63 4.36 5.35 7.35 5.63
Days Sales Outstanding (DSO)
46.68 48.90 51.13 52.39 59.66 61.60 66.17 72.51 83.07 76.72 81.20
Days Inventory Outstanding (DIO)
219.41 227.14 250.23 256.95 273.33 221.55 225.62 256.86 312.01 234.42 200.48
Days Payable Outstanding (DPO)
84.62 82.52 101.77 113.88 108.01 82.73 78.81 83.70 68.28 49.65 64.82
Cash Conversion Cycle (CCC)
181.47 193.51 199.59 195.46 224.98 200.43 212.99 245.66 326.79 261.49 216.87
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
28,130 26,386 18,905 17,125 30,665 31,748 31,972 33,301 59,901 54,003 54,133
Invested Capital Turnover
0.75 0.84 1.01 1.32 0.98 0.81 0.82 0.81 0.60 0.59 0.68
Increase / (Decrease) in Invested Capital
-1,337 -1,744 -7,481 -1,780 13,540 1,083 224 1,329 26,600 -5,898 130
Enterprise Value (EV)
94,013 82,179 95,872 108,013 144,006 140,468 141,435 160,059 202,091 187,106 220,512
Market Capitalization
93,966 85,668 102,208 103,388 123,014 118,129 116,163 130,419 148,422 138,980 175,037
Book Value per Share
$37.23 $40.16 $34.77 $19.62 $16.28 $16.16 $11.89 $6.86 $11.64 $10.93 $16.08
Tangible Book Value per Share
$2.19 $6.51 $2.58 ($15.13) ($41.14) ($37.56) ($41.49) ($52.38) ($84.16) ($75.27) ($59.98)
Total Capital
59,512 64,471 60,583 46,429 39,576 42,395 40,009 42,606 70,845 65,976 63,262
Total Debt
31,429 34,596 35,342 33,929 29,903 32,986 33,309 38,945 64,613 60,099 54,604
Total Long-Term Debt
29,182 30,193 34,190 29,510 26,950 32,895 33,222 37,354 63,170 56,549 50,005
Net Debt
47 -3,489 -6,336 4,625 20,992 22,339 25,272 29,640 53,669 48,126 45,475
Capital Expenditures (CapEx)
320 738 664 738 618 608 880 936 1,112 1,096 1,858
Debt-free, Cash-free Net Working Capital (DFCFNWC)
716 1,124 -70 -755 -353 -1,065 -749 -1,215 2,439 -2,492 -962
Debt-free Net Working Capital (DFNWC)
32,098 39,209 41,608 28,549 8,558 9,582 7,288 8,090 13,383 9,481 8,167
Net Working Capital (NWC)
29,851 34,806 40,456 24,130 5,605 9,491 7,201 6,499 11,940 5,931 3,568
Net Nonoperating Expense (NNE)
428 532 78 631 460 899 825 1,980 36 2,351 89
Net Nonoperating Obligations (NNO)
47 -3,489 -6,336 4,625 20,992 22,339 25,272 29,640 53,669 48,126 45,475
Total Depreciation and Amortization (D&A)
2,108 2,105 1,955 1,946 2,206 3,601 3,398 3,417 4,071 5,592 5,167
Debt-free, Cash-free Net Working Capital to Revenue
3.31% 4.89% -0.31% -3.18% -1.51% -4.19% -2.88% -4.62% 8.65% -7.46% -2.62%
Debt-free Net Working Capital to Revenue
148.18% 170.54% 182.10% 120.22% 36.63% 37.69% 28.05% 30.73% 47.47% 28.37% 22.22%
Net Working Capital to Revenue
137.80% 151.39% 177.06% 101.61% 23.99% 37.33% 27.72% 24.69% 42.36% 17.74% 9.71%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$9.15 $10.32 $2.71 $12.70 $12.96 $12.40 $10.34 $12.18 $12.56 $7.62 $14.33
Adjusted Weighted Average Basic Shares Outstanding
758M 748M 731M 661M 605M 586M 570M 538M 535M 537M 538M
Adjusted Diluted Earnings per Share
$9.06 $10.24 $2.69 $12.62 $12.88 $12.31 $10.28 $12.11 $12.49 $7.56 $14.23
Adjusted Weighted Average Diluted Shares Outstanding
766M 754M 735M 665M 609M 590M 573M 541M 538M 541M 542M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
752.09M 736.45M 720.56M 622.28M 589.81M 577.57M 557.03M 533.98M 535.92M 537.20M 539.07M
Normalized Net Operating Profit after Tax (NOPAT)
7,367 8,254 6,981 9,025 8,302 8,163 6,718 8,532 6,753 6,441 7,800
Normalized NOPAT Margin
34.01% 35.90% 30.55% 38.01% 35.54% 32.11% 25.86% 32.41% 23.96% 19.27% 21.22%
Pre Tax Income Margin
36.83% 39.85% 42.00% 40.19% 39.11% 31.99% 25.79% 27.91% 27.86% 13.79% 24.42%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
8.29 8.27 8.36 7.86 8.09 7.44 6.60 6.22 3.73 2.46 4.26
NOPAT to Interest Expense
6.73 6.55 1.58 6.48 6.44 6.47 5.61 6.07 2.35 2.04 2.83
EBIT Less CapEx to Interest Expense
7.99 7.69 7.85 7.33 7.61 6.96 5.86 5.56 3.35 2.11 3.58
NOPAT Less CapEx to Interest Expense
6.44 5.96 1.07 5.95 5.96 5.99 4.88 5.40 1.96 1.69 2.16
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
34.53% 0.00% 170.04% 41.78% 44.75% 51.69% 68.10% 64.04% 67.83% 118.14% 66.45%
Augmented Payout Ratio
61.44% 0.00% 329.71% 253.76% 142.96% 99.68% 152.52% 161.11% 67.83% 123.03% 66.45%

Quarterly Metrics And Ratios for Amgen

This table displays calculated financial ratios and metrics derived from Amgen's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - - 539,067,675.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 539,067,675.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 3.37
Growth Metrics
- - - - - - - - - - -
Revenue Growth
3.77% 19.84% 21.98% 20.07% 23.18% 10.86% 9.43% 9.43% 12.40% 8.58% 5.76%
EBITDA Growth
0.11% -0.68% -55.89% -7.97% 46.43% -4.16% 89.47% 20.02% 12.14% 12.75% -5.54%
EBIT Growth
-1.96% -22.65% -81.03% -32.29% 43.27% -8.61% 256.61% 41.20% 18.80% 41.73% 1.67%
NOPAT Growth
-24.65% -44.50% -56.25% -21.79% 4.03% 61.94% 48.90% 35.24% 10.90% 29.24% 125.28%
Net Income Growth
-19.27% -52.54% -103.98% -45.90% 63.58% -18.25% 1,630.97% 91.96% 13.64% 112.60% 5.14%
EPS Growth
-19.10% -52.67% -103.98% -46.30% 62.11% -17.61% 1,623.81% 92.03% 13.60% 109.40% 4.38%
Operating Cash Flow Growth
-7.32% -79.69% -35.24% -40.16% 29.38% 786.80% 101.89% -7.28% 31.17% -66.40% 57.37%
Free Cash Flow Firm Growth
-116.17% -3,574.71% -804.84% -90,615.89% -3,241.05% 130.45% 124.03% 126.03% 126.31% -70.78% -52.94%
Invested Capital Growth
8.11% 79.88% 67.70% 73.93% 76.48% -9.85% -7.68% -6.18% -7.05% 0.24% -0.55%
Revenue Q/Q Growth
-1.19% 18.73% -9.14% 12.64% 1.37% 6.86% -10.31% 12.64% 4.12% 3.23% -12.65%
EBITDA Q/Q Growth
10.39% -15.22% -29.41% 39.30% 75.65% -44.51% 39.54% -11.76% 64.11% -44.21% 16.91%
EBIT Q/Q Growth
14.37% -38.17% -54.81% 111.90% 142.01% -60.56% 76.32% -16.10% 103.63% -52.95% 26.49%
NOPAT Q/Q Growth
-21.69% -36.28% -39.37% 158.55% 4.15% -0.81% -44.26% 134.83% -14.59% 15.59% -2.83%
Net Income Q/Q Growth
25.45% -55.66% -114.73% 760.18% 279.36% -77.84% 175.92% -17.23% 124.58% -58.55% 36.46%
EPS Q/Q Growth
25.29% -55.90% -114.79% 757.14% 278.26% -77.59% 173.50% -17.19% 123.77% -58.68% 36.33%
Operating Cash Flow Q/Q Growth
-32.83% -80.51% 28.07% 256.89% 45.22% 33.60% -70.84% 63.91% 105.44% -65.78% 36.56%
Free Cash Flow Firm Q/Q Growth
-2,645.88% -3,494.20% 8.63% -0.60% -1.13% 132.76% -27.89% 8.98% 2.20% -63.62% 16.12%
Invested Capital Q/Q Growth
-2.04% 79.44% -0.95% -0.11% -0.60% -8.34% 1.44% 1.51% -1.52% -1.15% 0.63%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
73.84% 62.03% 57.03% 61.42% 61.07% 65.75% 63.58% 67.20% 67.75% 69.84% 68.16%
EBITDA Margin
52.17% 37.25% 28.94% 35.79% 62.01% 32.20% 50.10% 39.25% 61.87% 33.44% 44.76%
Operating Margin
29.28% 15.51% 13.31% 22.76% 24.07% 25.43% 14.46% 28.94% 26.43% 27.57% 30.94%
EBIT Margin
39.20% 20.41% 10.15% 19.10% 45.60% 16.83% 33.08% 24.64% 48.20% 21.96% 31.81%
Profit (Net Income) Margin
25.06% 9.36% -1.52% 8.89% 33.28% 6.90% 21.23% 15.60% 33.65% 13.51% 21.11%
Tax Burden Percent
88.85% 90.02% 166.18% 93.95% 91.26% 80.18% 87.68% 91.33% 82.02% 88.04% 87.28%
Interest Burden Percent
71.95% 50.93% -8.99% 49.56% 79.98% 51.14% 73.18% 69.32% 85.13% 69.87% 76.03%
Effective Tax Rate
11.15% 9.98% 0.00% 6.05% 8.74% 19.82% 12.32% 8.67% 17.98% 11.96% 12.72%
Return on Invested Capital (ROIC)
21.72% 8.45% 5.81% 14.17% 15.49% 11.97% 7.58% 16.06% 13.72% 16.50% 18.40%
ROIC Less NNEP Spread (ROIC-NNEP)
21.48% 7.54% 3.90% 11.57% 17.98% 9.56% 8.94% 14.11% 16.09% 14.23% 17.32%
Return on Net Nonoperating Assets (RNNOA)
100.56% 63.49% 31.69% 73.46% 91.34% 80.37% 81.88% 107.26% 90.59% 91.64% 105.55%
Return on Equity (ROE)
122.29% 71.93% 37.50% 87.63% 106.82% 92.33% 89.46% 123.32% 104.31% 108.14% 123.95%
Cash Return on Invested Capital (CROIC)
16.04% -42.59% -37.84% -42.20% -43.14% 21.67% 19.63% 19.10% 20.27% 14.19% 17.16%
Operating Return on Assets (OROA)
13.64% 7.09% 3.30% 6.52% 16.35% 5.95% 12.38% 9.62% 19.15% 8.85% 13.02%
Return on Assets (ROA)
8.72% 3.25% -0.49% 3.04% 11.94% 2.44% 7.95% 6.09% 13.37% 5.44% 8.64%
Return on Common Equity (ROCE)
122.29% 71.93% 37.50% 87.63% 106.82% 92.33% 89.46% 123.32% 104.31% 108.14% 123.95%
Return on Equity Simple (ROE_SIMPLE)
98.82% 0.00% 74.93% 52.83% 56.20% 0.00% 95.59% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1,796 1,144 694 1,794 1,868 1,853 1,033 2,426 2,072 2,395 2,327
NOPAT Margin
26.01% 13.96% 9.32% 21.38% 21.97% 20.39% 12.68% 26.43% 21.68% 24.27% 27.00%
Net Nonoperating Expense Percent (NNEP)
0.25% 0.91% 1.91% 2.60% -2.49% 2.41% -1.36% 1.96% -2.37% 2.27% 1.08%
Return On Investment Capital (ROIC_SIMPLE)
- 1.62% - - - 2.81% 1.62% 3.81% 3.23% 3.79% 3.50%
Cost of Revenue to Revenue
26.16% 37.97% 42.97% 38.58% 38.93% 34.25% 36.42% 32.80% 32.25% 30.16% 31.84%
SG&A Expenses to Revenue
19.60% 38.47% 24.28% 21.28% 19.11% 23.40% 30.89% 19.26% 21.44% 20.56% 18.59%
R&D to Revenue
15.63% 18.72% 18.03% 17.25% 17.05% 18.97% 18.24% 19.00% 19.88% 21.71% 19.95%
Operating Expenses to Revenue
44.56% 46.52% 43.72% 38.66% 37.00% 40.31% 49.12% 38.26% 41.32% 42.27% 37.22%
Earnings before Interest and Taxes (EBIT)
2,706 1,673 756 1,602 3,877 1,529 2,696 2,262 4,606 2,167 2,741
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,601 3,053 2,155 3,002 5,273 2,926 4,083 3,603 5,913 3,299 3,857
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
18.23 23.82 29.88 28.09 23.00 23.65 26.96 20.21 15.79 20.22 20.64
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
5.20 5.27 5.08 5.38 5.32 4.16 4.90 4.30 4.22 4.76 5.10
Price to Earnings (P/E)
18.45 22.10 39.87 53.18 40.93 33.98 28.21 22.68 21.69 22.70 24.32
Dividend Yield
3.19% 3.07% 3.08% 2.82% 2.76% 3.48% 2.93% 3.32% 3.33% 2.93% 2.75%
Earnings Yield
5.42% 4.53% 2.51% 1.88% 2.44% 2.94% 3.54% 4.41% 4.61% 4.41% 4.11%
Enterprise Value to Invested Capital (EV/IC)
4.95 3.37 3.44 3.71 3.81 3.46 3.94 3.57 3.60 4.07 4.31
Enterprise Value to Revenue (EV/Rev)
6.16 7.17 6.92 7.11 6.90 5.60 6.33 5.68 5.48 6.00 6.31
Enterprise Value to EBITDA (EV/EBITDA)
11.15 13.65 16.93 18.61 16.65 14.01 14.13 12.48 11.93 13.05 14.09
Enterprise Value to EBIT (EV/EBIT)
14.73 18.83 27.24 32.62 28.39 24.10 22.25 19.13 17.77 18.80 19.95
Enterprise Value to NOPAT (EV/NOPAT)
21.59 29.93 33.87 39.98 39.94 29.05 32.51 27.15 26.75 28.27 25.90
Enterprise Value to Operating Cash Flow (EV/OCF)
15.62 23.86 25.24 34.10 30.94 16.28 17.71 16.51 15.01 22.14 21.84
Enterprise Value to Free Cash Flow (EV/FCFF)
32.08 0.00 0.00 0.00 0.00 15.16 19.28 18.08 17.11 28.75 25.06
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
7.90 10.37 12.75 10.57 8.02 10.23 9.24 7.57 5.67 6.31 6.24
Long-Term Debt to Equity
7.71 10.14 11.96 9.64 7.55 9.62 8.70 7.24 5.45 5.78 5.65
Financial Leverage
4.68 8.42 8.13 6.35 5.08 8.41 9.16 7.60 5.63 6.44 6.10
Leverage Ratio
13.64 16.40 17.52 14.26 11.95 15.61 16.24 13.39 10.56 12.55 11.81
Compound Leverage Factor
9.81 8.35 -1.58 7.07 9.56 7.98 11.88 9.28 8.99 8.77 8.98
Debt to Total Capital
88.76% 91.20% 92.73% 91.36% 88.92% 91.09% 90.24% 88.33% 85.02% 86.31% 86.18%
Short-Term Debt to Total Capital
2.10% 2.04% 5.73% 8.06% 5.22% 5.38% 5.30% 3.84% 3.35% 7.27% 8.17%
Long-Term Debt to Total Capital
86.67% 89.17% 86.99% 83.30% 83.70% 85.71% 84.94% 84.49% 81.67% 79.04% 78.01%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
11.24% 8.80% 7.27% 8.64% 11.08% 8.91% 9.76% 11.67% 14.98% 13.69% 13.82%
Debt to EBITDA
4.08 4.37 5.30 5.30 4.48 4.50 3.75 3.54 3.30 3.23 3.44
Net Debt to EBITDA
1.74 3.63 4.50 4.52 3.81 3.60 3.18 3.03 2.73 2.69 2.72
Long-Term Debt to EBITDA
3.98 4.27 4.98 4.84 4.22 4.23 3.53 3.38 3.17 2.96 3.11
Debt to NOPAT
7.90 9.57 10.61 11.39 10.74 9.33 8.64 7.70 7.41 7.00 6.32
Net Debt to NOPAT
3.36 7.95 9.00 9.70 9.14 7.47 7.31 6.60 6.13 5.83 4.99
Long-Term Debt to NOPAT
7.71 9.35 9.95 10.39 10.11 8.78 8.13 7.36 7.12 6.41 5.72
Altman Z-Score
1.44 1.09 1.06 1.23 1.44 1.05 1.32 1.28 1.41 1.43 1.58
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.86 1.65 1.42 1.26 1.32 1.26 1.17 1.31 1.28 1.14 1.26
Quick Ratio
2.41 0.99 0.84 0.75 0.80 0.81 0.74 0.82 0.82 0.73 0.85
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-708 -25,456 -23,258 -23,398 -23,663 7,751 5,589 6,091 6,225 2,265 2,630
Operating Cash Flow to CapEx
1,112.90% 216.06% 299.57% 1,033.19% 1,389.49% 1,285.98% 338.44% 617.89% 1,074.31% 249.69% 307.44%
Free Cash Flow to Firm to Interest Expense
-0.93 -31.01 -28.23 -28.96 -30.49 10.38 7.73 8.78 9.09 3.47 4.00
Operating Cash Flow to Interest Expense
3.64 0.66 0.84 3.04 4.60 6.39 1.92 3.29 6.84 2.45 3.33
Operating Cash Flow Less CapEx to Interest Expense
3.31 0.35 0.56 2.75 4.27 5.89 1.36 2.75 6.20 1.47 2.25
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.35 0.35 0.33 0.34 0.36 0.35 0.37 0.39 0.40 0.40 0.41
Accounts Receivable Turnover
4.68 4.39 4.72 4.85 4.83 4.76 4.58 4.47 4.55 4.50 4.31
Inventory Turnover
1.45 1.17 1.45 1.75 2.08 1.56 1.63 1.70 1.78 1.82 1.83
Fixed Asset Turnover
4.99 4.96 5.15 5.32 5.55 5.35 5.38 5.39 5.38 5.08 5.00
Accounts Payable Turnover
5.53 5.35 6.74 6.53 7.34 7.35 6.26 4.70 4.88 5.63 4.42
Days Sales Outstanding (DSO)
78.02 83.07 77.32 75.30 75.52 76.72 79.73 81.72 80.20 81.20 84.68
Days Inventory Outstanding (DIO)
251.96 312.01 252.41 208.52 175.83 234.42 223.36 214.54 205.51 200.48 199.52
Days Payable Outstanding (DPO)
65.98 68.28 54.17 55.92 49.75 49.65 58.31 77.66 74.74 64.82 82.51
Cash Conversion Cycle (CCC)
263.99 326.79 275.55 227.91 201.60 261.49 244.78 218.60 210.97 216.87 201.69
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
33,383 59,901 59,334 59,269 58,914 54,003 54,778 55,604 54,761 54,133 54,475
Invested Capital Turnover
0.84 0.60 0.62 0.66 0.71 0.59 0.60 0.61 0.63 0.68 0.68
Increase / (Decrease) in Invested Capital
2,504 26,600 23,952 25,192 25,531 -5,898 -4,556 -3,665 -4,153 130 -303
Enterprise Value (EV)
165,289 202,091 204,356 219,794 224,520 187,106 215,937 198,309 197,068 220,512 234,956
Market Capitalization
139,562 148,422 150,044 166,450 173,133 138,980 167,366 150,133 151,926 175,037 189,671
Book Value per Share
$14.31 $11.64 $9.37 $11.05 $14.01 $10.93 $11.55 $13.81 $17.87 $16.08 $17.05
Tangible Book Value per Share
($39.27) ($84.16) ($83.81) ($79.90) ($74.54) ($75.27) ($71.04) ($66.69) ($59.80) ($59.98) ($57.25)
Total Capital
68,124 70,845 69,042 68,570 67,925 65,976 63,588 63,632 64,206 63,262 66,513
Total Debt
60,468 64,613 64,020 62,645 60,398 60,099 57,381 56,204 54,587 54,604 57,323
Total Long-Term Debt
59,040 63,170 60,061 57,117 56,854 56,549 54,013 53,760 52,434 50,005 51,886
Net Debt
25,727 53,669 54,312 53,344 51,387 48,126 48,571 48,176 45,142 45,475 45,285
Capital Expenditures (CapEx)
248 249 230 238 257 371 411 369 436 642 712
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1,790 2,439 2,566 1,916 987 -2,492 -1,521 674 -1,198 -962 -81
Debt-free Net Working Capital (DFNWC)
32,951 13,383 12,274 11,217 9,998 9,481 7,289 8,702 8,247 8,167 11,957
Net Working Capital (NWC)
31,523 11,940 8,315 5,689 6,454 5,931 3,921 6,258 6,094 3,568 6,520
Net Nonoperating Expense (NNE)
66 377 807 1,048 -962 1,226 -697 994 -1,144 1,062 508
Net Nonoperating Obligations (NNO)
25,727 53,669 54,312 53,344 51,387 48,126 48,571 48,176 45,142 45,475 45,285
Total Depreciation and Amortization (D&A)
895 1,380 1,399 1,400 1,396 1,397 1,387 1,341 1,307 1,132 1,116
Debt-free, Cash-free Net Working Capital to Revenue
-6.67% 8.65% 8.69% 6.19% 3.03% -7.46% -4.46% 1.93% -3.33% -2.62% -0.22%
Debt-free Net Working Capital to Revenue
122.80% 47.47% 41.56% 36.26% 30.73% 28.37% 21.36% 24.92% 22.93% 22.22% 32.13%
Net Working Capital to Revenue
117.48% 42.36% 28.16% 18.39% 19.84% 17.74% 11.49% 17.92% 16.94% 9.71% 17.52%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$3.23 $1.43 ($0.21) $1.39 $5.27 $1.17 $3.22 $2.66 $5.98 $2.47 $3.37
Adjusted Weighted Average Basic Shares Outstanding
535M 535M 536M 537M 537M 537M 538M 538M 538M 538M 540M
Adjusted Diluted Earnings per Share
$3.22 $1.42 ($0.21) $1.38 $5.22 $1.17 $3.20 $2.65 $5.93 $2.45 $3.34
Adjusted Weighted Average Diluted Shares Outstanding
538M 538M 536M 541M 542M 541M 541M 541M 542M 542M 544M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
535.18M 535.92M 536.43M 537.33M 537.53M 537.20M 537.71M 538.36M 538.48M 539.07M 539.71M
Normalized Net Operating Profit after Tax (NOPAT)
1,796 1,144 694 1,794 1,868 1,853 1,033 2,426 2,072 2,395 2,228
Normalized NOPAT Margin
26.01% 13.96% 9.32% 21.38% 21.97% 20.39% 12.68% 26.43% 21.68% 24.27% 25.86%
Pre Tax Income Margin
28.21% 10.40% -0.91% 9.47% 36.47% 8.61% 24.21% 17.08% 41.03% 15.35% 24.18%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
3.57 2.04 0.92 1.98 5.00 2.05 3.73 3.26 6.72 3.32 4.17
NOPAT to Interest Expense
2.37 1.39 0.84 2.22 2.41 2.48 1.43 3.50 3.02 3.67 3.54
EBIT Less CapEx to Interest Expense
3.24 1.73 0.64 1.69 4.66 1.55 3.16 2.73 6.09 2.34 3.09
NOPAT Less CapEx to Interest Expense
2.04 1.09 0.56 1.93 2.08 1.98 0.86 2.96 2.39 2.68 2.46
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
58.90% 67.83% 122.96% 150.06% 112.70% 118.14% 82.64% 75.15% 72.03% 66.45% 66.71%
Augmented Payout Ratio
58.90% 67.83% 122.96% 150.06% 112.70% 123.03% 82.64% 75.15% 72.03% 66.45% 66.71%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, investor-focused snapshot of Amgen (AMGN) using the last four years of quarterly data across income statements, balance sheets, and cash flow statements. The bullets below highlight trends most relevant to cash generation, profitability, and leverage.

  • Revenue has trended higher over the four-year window, rising from about $6.84B in 2022 Q4 to about $9.87B in 2025 Q4.
  • Net income attributable to common shareholders grew to about $1.333B in 2025 Q4, up from about $0.627B in 2024 Q4.
  • Diluted earnings per share advanced to about $2.45 in 2025 Q4 from about $1.17 in 2024 Q4.
  • Free cash flow in 2025 Q4 was positive, with net cash from continuing operating activities around $1.60B and capex about $0.64B, yielding roughly $0.96B in free cash flow for the quarter.
  • Dividend per share has shown growth, with a representative quarterly dividend per share of $2.38 in 2025 Q1 versus $2.13 in 2024 Q1, indicating ongoing shareholder returns.
  • R&D investment remains robust, with R&D expense around $2.14B in 2025 Q4 (and generally high, year-over-year), supporting a continued product pipeline and long‑term growth potential.
  • The balance sheet shows a large asset base (near $90B) alongside sizable liabilities (roughly $80B) and equity in the low-to-mid single digits, indicating a leveraged but generally stable capital structure.
  • Retained earnings and some equity line items display negative values in certain periods, reflecting historical restatements and accumulated variances rather than immediate liquidity concerns.
  • Cash flow from operations has shown volatility, with 2025 Q4 CFO about $1.6B, which is notably below prior quarters (e.g., 2025 Q3 CFO around $4.7B), suggesting quarterly variability in cash generation.
  • Debt load remains substantial, with long-term debt in the low-$50Bs to mid-$50Bs range across recent quarters and total liabilities well above $80B, posing ongoing interest and leverage considerations.
05/24/26 02:28 PM ETAI Generated. May Contain Errors.

Amgen Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Amgen's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

The last 5 years of Amgen's net income performance:
  • 2021: $5.89 billion
  • 2022: $6.55 billion
  • 2023: $6.72 billion
  • 2024: $4.09 billion
  • 2025: $7.71 billion
Find out what analysts predict for Amgen in the coming months.

Amgen's total operating income in 2025 was $9.08 billion, based on the following breakdown:
  • Total Gross Profit: $24.71 billion
  • Total Operating Expenses: $15.63 billion

Over the last 10 years, Amgen's total revenue changed from $21.66 billion in 2015 to $36.75 billion in 2025, a change of 69.7%.

Amgen's total liabilities were at $81.93 billion at the end of 2025, a 4.7% decrease from 2024, and a 88.9% increase since 2015.

In the past 10 years, Amgen's cash and equivalents has ranged from $3.24 billion in 2016 to $11.97 billion in 2024, and is currently $9.13 billion as of their latest financial filing in 2025.

Over the last 10 years, Amgen's book value per share changed from 37.23 in 2015 to 16.08 in 2025, a change of -56.8%.



Financial statements for NASDAQ:AMGN last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners